immunotoxin การใช้

• Resimmune is an immunotoxin that is in clinical trials in Cutaneous T cell lymphoma patients.
• The term " immunotoxin " is also sometimes used ( incorrectly ) to label undesirable immunosuppressants, such as various pollutants.
• An "'immunotoxin "'is a human-made protein that consists of a targeting portion linked to a toxin.
• Calcium imaging observation following immunotoxin use showed that some correlated firing still remained where coupled voltage clamp recording showed significant reduction in correlated firing.
• Three immunotoxin drugs have been studied in patients at the NIHNational Cancer Institute in the U . S . : BL22, HA22 and LMB-2.
• One disadvantage of these types of immunotoxin for clinical use is their relatively narrow therapeutic window and associated potentially life threatening toxicities at dose levels that are therapeutic.
• On the 1 November 2005 Cambridge Antibody Technology announced it was acquiring two anti-CD22 immunotoxin products from Genencor, namely GCR-3888 and GCR-8015.
• CAT-3888 was succeeded by moxetumomab pasudotox ( CAT-8015, HA22 ), an anti-CD22 immunotoxin comprising a modified Pseudomonas exotoxin and an anti-CD22 antibody fragment.
• "' The Recombinant Immunotoxin Collaborative Group ( RICG ) "'is a group of scientists specialising in immunology, biochemistry and molecular biology from the United Kingdom and Italy.
• In 2008, the Provencio lab was able to specifically destroy melanopsin cells in the fully developed mouse retina using an immunotoxin made of an anti-melanopsin antibody conjugated to the protein saporin.
• Technically, CAT-3888 is an anti-CD22 immunotoxin fusion protein between a murine anti-CD22 disulfide-linked Fv ( dsFv ) antibody fragment and an edited copy of bacterial Pseudomonas exotoxin PE38.
• The researchers at the National Cancer Institute in Bethesda, Md ., developed and tested the drug, a so-called immunotoxin known as BL22, on 16 patients with hairy cell leukemia untreatable by the usual chemotherapy.
• "' Resimmune "'or A-dmDT390-bisFv ( UCHT1 ) is an experimental drug & mdash; an anti-T cell immunotoxin & mdash; that is being investigated for treatment of blood cancers such as cutaneous T cell lymphoma ( CTCL ).
• Furthermore, since immunotoxin treatment to kill starburst amacrine cells shows no difference in the formation of eye-specific retinogeniculate projections while treatment with epibatidine does, it could suggest that some sort of retinal activity is essential for the eye-specific layer formation, but not retinal waves.
• This partnership has resulted in a long list of medical milestones, including the development of chemotherapy; the first use of an immunotoxin to treat a malignancy; identification of the genes that cause kidney cancer, leading to the development of six new, targeted treatments for advanced kidney cancer; the discovery that lithium helps depression; the first gene therapy; the first AIDS treatment; and the development of tests to detect AIDS / HIV and hepatitis viruses in blood, which led to a safer blood supply.